FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or antigen-binding fragment thereof having inverse antagonism, which specifically binds to conformational epitope 1 of human cannabinoid receptor 1 (CB1). Also disclosed is a conjugate containing said antibody, a host cell expressing said antibody. Also disclosed are methods of conferring properties of antagonist or agonist CB1 receptor, treatment and diagnostics.
EFFECT: invention provides effective treatment of diseases associated with cannabinoid receptor 1 (CB1).
34 cl, 31 dwg, 34 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
